ShareValue scores for 6915.HK: Valuation 36, Quality 65, Growth 50, Health 65.
6915.HKHKEX
Jiangxi Institute of Biological Products Inc.
HK$5.95
(-0.50%)
Updated
6915.HKHKEX
Jiangxi Institute of Biological Products Inc.
Updated
Pulse
Pulse
Fundamental Rating
Value Trap Risk
If P/E met sector median
Rating
Trap Risk
P/E to median
vs Hong Kong-listed Healthcare stocks
Company Details
Jiangxi Institute of Biological Products Inc. manufactures and exports biological products including Tetanus Antitoxin and Veterinary Medicine. The company offers Antitoxin Formulations, Active Pharmaceutical Ingredients, Equine Byproducts, essential oils, and plant extracts. It serves businesses in China and international markets. The company was founded in 1969 and is based in Ji'an, China. Jiangxi Institute of Biological Products Inc. is a subsidiary of Shenzhen Qianhai Tianzheng Biotechnology Co., Ltd.
Score Analysis
AI Investment Thesis
Valuation model rates Jiangxi Institute of Biological Products Inc. overvalued versus Hong Kong-listed Healthcare stocks: P/S of 8.32 is higher than 75% of peers and EV/EBITDA of 13.8 higher than 71%.
Quality is the standout: a 33.0% net margin and 72.3% H1 gross margin reflect a high-priced, niche antiserum franchise, though revenue fell 16.5% and adjusted profit 21.7%.
Interim results on 31 August 2026 showed revenue down 16.5% to RMB83.3mn and adjusted net profit down 21.7% to RMB38.7mn, prompting a roughly 33% share-price slide.